Cumulative effect of simvastatin, l-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer’s disease

[1]  J. Becker,et al.  Cerebral Blood Flow Predicts Conversion of Mild Cognitive Impairment into Alzheimer's Disease and Cognitive Decline: An Arterial Spin Labeling Follow-up Study. , 2021, Journal of Alzheimer's disease : JAD.

[2]  Julia J. Mack,et al.  ENDOTHELIAL CONTROL OF CEREBRAL BLOOD FLOW. , 2021, The American journal of pathology.

[3]  H. El-Abhar,et al.  Activated ROCK/Akt/eNOS and ET-1/ERK pathways in 5-fluorouracil-induced cardiotoxicity: modulation by simvastatin , 2020, Scientific Reports.

[4]  G. Santulli,et al.  Arginine and Endothelial Function , 2020, Biomedicines.

[5]  W. M. van der Flier,et al.  Cerebral Blood Flow and Cognitive Functioning in a Community-Based, Multi-Ethnic Cohort: The SABRE Study , 2018, Front. Aging Neurosci..

[6]  M. Montero‐Odasso,et al.  The Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review , 2018, Journal of Alzheimer's disease : JAD.

[7]  A. Sierra-Marcos.  Regional Cerebral Blood Flow in Mild Cognitive Impairment and Alzheimer's Disease Measured with Arterial Spin Labeling Magnetic Resonance Imaging , 2017, International journal of Alzheimer's disease.

[8]  A. Butte,et al.  Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease , 2017, Alzheimer's Research & Therapy.

[9]  Z. Leonenko,et al.  Recent Progress in Alzheimer's Disease Research, Part 1: Pathology. , 2017, Journal of Alzheimer's disease : JAD.

[10]  Dong Young Lee,et al.  Heterogeneity of Regional Brain Atrophy Patterns Associated with Distinct Progression Rates in Alzheimer’s Disease , 2015, PloS one.

[11]  J. Pretnar-Oblak.  Cerebral Endothelial Function Determined by Cerebrovascular Reactivity to L-Arginine , 2014, BioMed research international.

[12]  D. Alsop,et al.  Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer's disease: a pilot study. , 2012, Current Alzheimer research.

[13]  R. Marshall,et al.  Statins and Cerebral Hemodynamics , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  X. Tong,et al.  Age-Dependent Rescue by Simvastatin of Alzheimer's Disease Cerebrovascular and Memory Deficits , 2012, The Journal of Neuroscience.

[15]  Alessandra Bertoldo,et al.  Automatic selection of arterial input function on dynamic contrast-enhanced MR images , 2011, Comput. Methods Programs Biomed..

[16]  J. Schott,et al.  What is the clinically relevant change on the ADAS-Cog? , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[17]  M. Zaletel,et al.  Cerebrovascular reactivity to l‐arginine in the anterior and posterior cerebral circulation in migraine patients , 2011, Acta neurologica Scandinavica.

[18]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[19]  K. Rockwood,et al.  Advances in perfusion magnetic resonance imaging in Alzheimer's disease , 2011, Alzheimer's & Dementia.

[20]  W. Brown,et al.  Review: Cerebral microvascular pathology in ageing and neurodegeneration , 2011, Neuropathology and applied neurobiology.

[21]  M. Zaletel,et al.  Differences between Cerebrovascular Reactivity to L-Arginine in the Anterior and Posterior Cerebral Circulation , 2011, Cerebrovascular Diseases.

[22]  Salvatore Mazza,et al.  Primary cerebral blood flow deficiency and Alzheimer's disease: shadows and lights. , 2011, Journal of Alzheimer's disease : JAD.

[23]  P. Carvey,et al.  Evidence of angiogenic vessels in Alzheimer’s disease , 2009, Journal of Neural Transmission.

[24]  Alessandra Bertoldo,et al.  Nonlinear Stochastic Regularization to Characterize Tissue Residue Function in Bolus-Tracking MRI: Assessment and Comparison With SVD, Block-Circulant SVD, and Tikhonov , 2009, IEEE Transactions on Biomedical Engineering.

[25]  L. d’Uscio,et al.  Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. , 2009, Trends in pharmacological sciences.

[26]  Kazuto Nakamura,et al.  Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice. , 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[27]  A Hofman,et al.  Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[28]  T. Fujii,et al.  Statins restore ischemic limb blood flow in diabetic microangiopathy via eNOS/NO upregulation but not via PDGF-BB expression Authors: , 2008 .

[29]  C. Stefanadis,et al.  L-Arginine, the substrate for NO synthesis: an alternative treatment for premature atherosclerosis? , 2007, International journal of cardiology.

[30]  M. Zaletel,et al.  Associations between systemic and cerebral endothelial impairment determined by cerebrovascular reactivity to L-arginine. , 2007, Endothelium : journal of endothelial cell research.

[31]  C. Frampton,et al.  Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure , 2006, Heart.

[32]  M. Zaletel,et al.  Cerebrovascular Reactivity to L-Arginine in Patients with Lacunar Infarctions , 2006, Cerebrovascular Diseases.

[33]  R J Harvey,et al.  Donepezil for dementia due to Alzheimer's disease. , 2006, The Cochrane database of systematic reviews.

[34]  C. Robertson,et al.  Comparison of tetrahydrobiopterin and L-arginine on cerebral blood flow after controlled cortical impact injury in rats. , 2004, Journal of neurotrauma.

[35]  J. McCarten,et al.  Change in the mini-mental state exam in Alzheimer's disease over 2 years: the experience of a dementia clinic. , 2004, Journal of Alzheimer's disease : JAD.

[36]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[37]  K. Walsh,et al.  HMG-CoA reductase inhibitors promote cholesterol-dependent Akt/PKB translocation to membrane domains in endothelial cells. , 2003, Cardiovascular research.

[38]  Kenneth Rockwood,et al.  Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. , 2002, Archives of neurology.

[39]  C. Schweiger.  [Statins and the risk of dementia]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[40]  Richard M. Leahy,et al.  BrainSuite: An Automated Cortical Surface Identification Tool , 2000, MICCAI.

[41]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[42]  T. Meinertz,et al.  Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus , 2000, Diabetologia.

[43]  Qualitative Analysis of the Clinician Interview-Based Impression of Change (Plus): Methodological Issues and Implications for Clinical Research , 2000, International Psychogeriatrics.

[44]  I. Shiojima,et al.  The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. , 2000, Nature Medicine.

[45]  M. Moskowitz,et al.  Endothelial Nitric Oxide Synthase-Dependent Cerebral Blood Flow Augmentation by L-Arginine After Chronic Statin Treatment , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[46]  N. Delanty,et al.  Neuroprotective properties of statins in cerebral ischemia and stroke. , 1999, Stroke.

[47]  H.-J. Möller,et al.  The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1 , 1999, Dementia and Geriatric Cognitive Disorders.

[48]  M. Moskowitz,et al.  Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[49]  U. Laufs,et al.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.

[50]  R. Petersen,et al.  Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs: Additions to the Alzheimer's Disease Assessment Scale That Broaden Its Scope , 1997, Alzheimer disease and associated disorders.

[51]  D. Drachman,et al.  The Cognitive Assessment Screening Test (CAST) for Dementia , 1996, Journal of geriatric psychiatry and neurology.

[52]  D. Selkoe.  The molecular pathology of Alzheimer's disease , 1991, Neuron.

[53]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[54]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.